Primary sources underpin the regulatory, programme, price and technical claims. Trade coverage, job listings and podcast/video searches were used for discovery and question generation, not to establish supplier performance or legal conclusions. URLs below identify the cited records; dynamic pages should be rechecked before a purchasing decision.
Regulation, courts and official guidance
- FDA — GLP-1 compounding policy clarification: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- FDA — Drug Shortages database: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- Fifth Circuit — tirzepatide opinion, August 27, 2026: https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
- Fifth Circuit — semaglutide opinion, revised September 1, 2026: https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10758/pdf/USCOURTS-ca5-25-10758-0.pdf
- FDA — proposed exclusion from 503B bulks list: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- FDA — concerns with unapproved GLP-1 drugs: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA — 503A essentially-copy guidance: https://www.fda.gov/media/98973/download
- FDA — prescription requirement under 503A: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-requirement-under-section-503a-federal-food-drug-and-cosmetic-act-guidance-industry
- FDA — 503A and 503B statutory-framework presentation: https://www.fda.gov/media/162166/download
- US Code — 21 USC 353b: https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353b.htm
- FDA — compounding questions and answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA — registered outsourcing facilities: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- FDA — Form 483 FAQs: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- FDA — wholesale distributor and logistics-provider reporting: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
- FDA — DSCSA exemptions: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- California Board of Pharmacy — nonresident licensing: https://www.pharmacy.ca.gov/applicants/phy.shtml
- California Board of Pharmacy — July 2026 requirements: https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
- California Board of Pharmacy — nonresident sterile-compounding application: https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
- CMS — Medicare GLP-1 Bridge: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- HHS — business-associate guidance: https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
- FDA — November 9, 2026 safety communication: https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
Manufacturer programmes and supplier documentation
- LillyDirect — patient FAQs: https://www.lilly.com/lillydirect/faq
- LillyDirect — Zepbound access and pricing: https://www.lilly.com/lillydirect/zepbound
- LillyDirect — Zepbound full terms: https://www.lilly.com/lillydirect/zepbound/zepbound-tirzepatide-full-terms-conditions
- LillyDirect — Foundayo access and pricing: https://www.lilly.com/lillydirect/foundayo
- NovoCare — healthcare-professional delivery information: https://www.novocare.com/hcp/delivery.html
- NovoCare — current Wegovy savings offers: https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- NovoCare — Wegovy price guide, including historical promotional footnotes: https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
- McKesson — pharmaceutical distribution: https://www.mckesson.com/business-solutions/pharmaceutical-medical-products-distribution/pharmaceutical-distribution-services/
- Photon — product FAQ: https://photonhealth.com/faq
- Photon — order and prescription status definitions: https://docs.photon.health/docs/order-rx-status-retail-pharmacycourier-delivery
Limitations: Public evidence does not establish negotiated acquisition prices, facility-level available capacity, account approval, all-state permissions or comparative service outcomes. This document is procurement decision support, not legal clearance or individual medical advice.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- accessdata.fda.gov · Source 2 ↗https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- govinfo.gov · Source 3 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
- govinfo.gov · Source 4 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10758/pdf/USCOURTS-ca5-25-10758-0.pdf
- fda.gov · Source 5 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- fda.gov · Source 6 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- fda.gov · Source 7 ↗https://www.fda.gov/media/98973/download
- fda.gov · Source 8 ↗https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prescription-requirement-under-section-503a-federal-food-drug-and-cosmetic-act-guidance-industry
- fda.gov · Source 9 ↗https://www.fda.gov/media/162166/download
- govinfo.gov · Source 10 ↗https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353b.htm
- fda.gov · Source 11 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- fda.gov · Source 12 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- fda.gov · Source 13 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- fda.gov · Source 14 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
- fda.gov · Source 15 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- pharmacy.ca.gov · Source 16 ↗https://www.pharmacy.ca.gov/applicants/phy.shtml
- pharmacy.ca.gov · Source 17 ↗https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
- pharmacy.ca.gov · Source 18 ↗https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
- cms.gov · Source 19 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- hhs.gov · Source 20 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
- fda.gov · Source 21 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
- lilly.com · Source 22 ↗https://www.lilly.com/lillydirect/faq
- lilly.com · Source 23 ↗https://www.lilly.com/lillydirect/zepbound
- lilly.com · Source 24 ↗https://www.lilly.com/lillydirect/zepbound/zepbound-tirzepatide-full-terms-conditions
- lilly.com · Source 25 ↗https://www.lilly.com/lillydirect/foundayo
- novocare.com · Source 26 ↗https://www.novocare.com/hcp/delivery.html
- novocare.com · Source 27 ↗https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- novocare.com · Source 28 ↗https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
- mckesson.com · Source 29 ↗https://www.mckesson.com/business-solutions/pharmaceutical-medical-products-distribution/pharmaceutical-distribution-services/
- photonhealth.com · Source 30 ↗https://photonhealth.com/faq
- docs.photon.health · Source 31 ↗https://docs.photon.health/docs/order-rx-status-retail-pharmacycourier-delivery